MPM keeps building

How MPM is deploying three investment vehicles to support company building

MPM Capital’s new $400 million BioVentures 2018 fund will complement the firm’s cancer-focused initiatives and enable it to continue its company building strategy.

BioVentures 2018 closed on Feb. 21 and follows in the footsteps of BioVentures 2014 fund, which closed at $400 million in 2015 with a

Read the full 474 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE